To see all protocols that comply with the WHO Essential Medicine List 
  • This clinical procedure outlines the management of an extravasation with the following vesicant drugs: amsacrine, dactinomycin (actinomycin D), daunorubicin, doxorubicin, epirubicin, idarubicin and mitomycin. Only health care professionals who have expertise and the knowledge of cytotoxic drugs and who have attained competency as per institutional guidelines in extravasation management should perform this procedure.
  • Extravasation of a vesicant is a medical emergency; early detection and prompt appropriate action is required to prevent necrosis and functional loss of the tissue or limb involved.

This procedure should be read in conjunction with the Extravasation management document and the Immediate management of extravasation flow chart.

This document reflects what is currently regarded as safe practice. While every effort has been made to ensure the accuracy of the content at the time of publication, the Cancer Institute NSW does not accept any liability, with respect to loss, damage, injury or expense arising from any such errors or omission in the contents of this work. Any reference throughout the document to specific pharmaceuticals and/or medical products as examples does not imply endorsement of any of these products. Use is subject to eviQ’s disclaimer available at

Send feedback for this page

First approved:
Last reviewed:
Review due:

The currency of this information is guaranteed only up until the date of printing, for any updates please check:

27 May 2020